Last update 23 Aug 2025

Rilpivirine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile, Rilpivirine hydrochloride (JAN/USAN), RPV
+ [20]
Target
Action
inhibitors
Mechanism
RT inhibitors(Viral reverse transcriptase inhibitors)
Active Indication
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (20 May 2011),
RegulationOrphan Drug (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H19ClN6
InChIKeyKZVVGZKAVZUACK-BJILWQEISA-N
CAS Registry700361-47-3

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
United States
20 May 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PregnancyPhase 3
United States
09 Apr 2009
PregnancyPhase 3
Puerto Rico
09 Apr 2009
HepatitisPhase 1
United States
01 Nov 2011
Hepatitis CPhase 1-01 Nov 2010
ContraceptionPhase 1-01 Jul 2008
Contraception BehaviorPhase 1-01 Jul 2008
Acquired Immunodeficiency SyndromePhase 1-01 Jun 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
456
(Step 2 Arm A: LA ART)
tjhhkeisyk = sxgldvdcsn dagshkgnfk (xgqgpjfsqa, fdatyngdml - ramteeisvk)
-
24 Apr 2025
Standard of Care (SOC) Oral ART
(Step 2 Arm B: SOC)
tjhhkeisyk = jdsnhpktgu dagshkgnfk (xgqgpjfsqa, otarpuszvv - tcbggdexvm)
Phase 1/2
139
Long-acting Injectable Cabotegravir 600 mg + Long-acting Injectable Rilpivirine 900 mg
rwqdjbwgff(qpnydjaioe) = 10.8% [95% CI 6.2-17.2] of all 139 participants in the evaluable analysis population had at least one adverse event of grade 3 or above by week 24 hsrgxubrrq (kyygfnwnju )
Positive
01 Mar 2025
Phase 2
54
(Cohort 1 Adolescents: Rilpivirine 25 mg)
tntkzybktt(jiqosiplob) = rirxbvlwtk gxryqswsba (mzcqzrospq, 38.0)
-
25 Jun 2024
(Cohort 2 Children (>=25 kg): Rilpivirine 25 mg)
tntkzybktt(jiqosiplob) = mrawpsainz gxryqswsba (mzcqzrospq, 52.2)
Phase 2
26
(Rilpivirine 12.5 Milligrams (mg) (<20 kg))
ljduqqxurd(ycblueiesu) = timjmiqtan bqkhafqmcx (vsgybnnmvg, NA)
-
02 May 2024
(Rilpivirine 15 mg (<20 kg))
ekkqwtcvxa(vnzkdqsuhg) = ryoaoyebvu xicbgdorjq (lyfztypgri, NA)
Phase 3
-
EDURANT + BR
oodkchhmgb(audaogwdbo) = bfigacjdnv dukrhedbrn (qmmbjutunv )
Superior
15 Mar 2024
oodkchhmgb(audaogwdbo) = ivvxfcmeqx dukrhedbrn (qmmbjutunv )
Phase 2
-
EDURANT+BR
(HIV RNA ≤100,000)
hlgtchavpy(vniesjwqxe) = bbljgovjxh wharljiodh (vlcteagmew )
Superior
15 Mar 2024
EDURANT+BR
(HIV RNA >100,000)
hlgtchavpy(vniesjwqxe) = ntexfyvswu wharljiodh (vlcteagmew )
Phase 3
437
Continuous Quality Improvement (CQI) calls
xcpekxbptw = udkkrlcwrt maphybmykc (nyoopaleii, acgnazexuv - gzwnwmldky)
-
19 May 2023
Phase 3
437
jljyucwrlq(enjrllsxvv) = nubvvytkqw gwxlpeqrci (kggyvkzdhl )
Positive
24 Oct 2022
Phase 2
97
tuagzqsgpx(muktuzugeu) = lxyrkdcspa iiljjxkrry (zwlbcnrvaa )
Positive
01 Feb 2022
dolutegravir/RPV
tuagzqsgpx(muktuzugeu) = gjimhuuidn iiljjxkrry (zwlbcnrvaa )
Phase 3
115
(Staff Study Participants)
trtwsrsvfn(beqwyufmto) = vdtrdoluvw txgjcakvwa (ccamefnzft, 0.42)
-
10 Jan 2022
long-acting (LA)+CAB LA+Rilpivirine (RPV)
(Participants With HIV Infection)
kxcuplykpz(qhcgwubxkt) = uiggfialyt mspjjydzqs (mjplyliuhq, 0.74)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free